Drugs / 1278863A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01047397 | Mar 2010 → Feb 2011 | kidney disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1278863A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01047397 ↗ |
| Action | Inhibit | “through inhibition of hypoxia-inducible factor (HIF)-prolyl hydroxylases (EGLNs)” NCT01047397 ↗ |
| Modality | Small molecule | “novel small molecule agent” NCT01047397 ↗ |
| Route | Oral | “repeat oral doses” NCT01047397 ↗ |